In an exclusive interview with Fortune, Alterra Labs' CEO Akash Kapoor and Oak Partner Vig Chandramouli discuss the company's $12.5 million seed round and its mission to build the training environments needed to safely advance AI in healthcare.
Read the full piece: fortune.com/2026/11/10/alter…
Vumedi is expanding its AI capabilities, building on its $104M Series B.
Physicians face a growing volume of research and new therapies, and keeping up is only half the challenge. Applying that evidence to a specific patient often depends on how experienced specialists approach the same problem, and that kind of insight rarely shows up in the literature.
Vumedi is a peer-to-peer learning community with more than 100,000 physician-led videos and nearly 5,000 podcast episodes across 21+ specialties. Many AI tools summarize published research. Vumedi AI starts with how practicing specialists actually apply it. In less than a year, more than 150,000 verified clinicians have used it, generating over one million interactions.
We're proud to partner with Roman Giverts and the entire Vumedi team as they make physicians’ collective expertise more accessible.
Read more: oakhcft.com/blog-post/vumedi…
We’re proud to announce that Oak led Alterra Labs’ $12.5M seed round.
AI is moving quickly from administrative tasks into complex applications like clinical reasoning and drug discovery. But models that excel on general benchmarks still struggle with the nuance and edge cases clinicians and scientists face every day. In healthcare, those failures carry real consequences for patients.
Alterra builds reinforcement learning environments and evaluations that train AI to do complex clinical and scientific work safely. Its environments simulate real-world systems, while its team of licensed physicians, scientists and ML researchers design tasks and evaluation criteria. Most players in this space treat healthcare as one vertical among many. Alterra is healthcare-first, with the technical rigor to partner with the most sophisticated AI labs.
AI has extraordinary potential to transform healthcare and life sciences, but realizing it will require the infrastructure to evaluate and improve these systems where reliability matters most. We're proud to partner with Akash Kapoor and the entire team as they tackle one of AI's most consequential challenges.
Read more: oakhcft.com/blog-post/making…
What happens if regulatory barriers to autonomous clinical AI fall faster than expected?
Clinical AI has the FDA to contend with – but recent signals (a new CDRH framework for assessing AI “competency,” ARPA-H’s new ADVOCATE program funding cardiovascular AI) suggest the path might be shorter than expected.
In his latest blog post, Venture Partner Duncan Greenberg explores that question and breaks down nine emerging categories of startups already building for that future.
Read the full piece: oakhcft.com/blog-post/machin…
Following @HalluminateAI's $30M Series A, CEO @Jerr_Wu joined @tbpn to discuss how the company is building training environments to help frontier AI labs improve their models.
The conversation covers what these environments look like, how performance is evaluated and scored, and what the next five years could hold for the space.
Watch here: youtube.com/live/SiyFdWvIx1s…
We're proud to announce that Oak HC/FT led Vitalize's $31M Series A.
Clinical staffing is one of the largest line items on every health system's P&L – and it still runs on spreadsheets, group texts, and heroics. Premium labor alone costs U.S. health systems an estimated $50B a year, much of it because the process for deploying staff hasn't kept pace with how fast demand actually changes.
Vitalize has built the air traffic control layer for healthcare's workforce – unifying staffing, scheduling, and capacity into a single platform that doesn't just recommend a fix, it executes one. Customers are seeing 10-20% reductions in premium labor spend, with go-lives now measured in weeks.
We back founders with earned insight into the problems they're solving, and Veeraj Shah and Sanketh Andhavarapu have exactly that. Proud to partner with them and the entire Vitalize team.
Read more: oakhcft.com/blog-post/air-tr…
.@annielamont recently joined @MollySOShea on Sourcery to explore how AI is reshaping the line between healthcare and fintech, why AI in biotech is taking off, and how the AI shift is changing the way Oak evaluates companies.
In this clip, Annie discusses how Oak portfolio company @DevotedHealth is leveraging AI to build a business that could become “almost impossible to compete against in the future.”
Watch the full episode: youtube.com/watch?v=sjd_G6-k…
Annie Lamont says Devoted Health is one of “the best examples of AI applied to healthcare in the world right now.”
“Over the last year, they've tripled the size of their company. They halved the amount of their operating ratio. They dramatically increased their EBITDA.”
“You have a company that is almost impossible to compete against in the future.”
BREAKING: Only 10% of AI companies are worth their valuations. The other 90% aren't.
Annie Lamont, Co-Founder & Managing Partner of @OakHCFT
#1 healthcare investor on the Midas List, 40+ years investing, 70+ exits, 15 IPOs, & $7B+ firm that just closed $2B Fund VI
FULL INTERVIEW
We sat down at the @NYSE to talk AI drug discovery, China's rise in pharma research, Devoted Health as the leading example of AI in healthcare, & frontier labs as the next healthcare acquirers.
We cover:
› Pharma now sends 50% of its outside research spending to China, a shift from the last 4 years
› @chaidiscovery's AI makes antibody design labs 100x more productive
› @DevotedHealth tripled in size in the last year
› Oak committed $100M on day 1 to Auger, ex-Amazon exec Dave Clark's AI supply chain startup
› Oak’s latest investment in Halluminate, a data research lab building reinforcement-learning environments for financial services
𝐓𝐈𝐌𝐄𝐒𝐓𝐀𝐌𝐏𝐒
(00:00) Annie Lamont, Co-Founder & MP at Oak HC/FT
(00:56) How AI reshaped Healthcare & Fintech
(05:35) Why AI in biotech is finally exploding
(08:35) The China threat to American drug development
(17:03) Are Hospitals actually at risk from AI?
(23:26) How AI will transform your healthcare experience
(26:32) How the AI shift changed the way Oak evaluates companies
(32:58) How M&A is changing in Healthcare
(35:43) What a great acquisition looks like
(50:26) Halluminate
(53:20) Augur
(58:49) What's kept Annie Lamont going for four decades
Today, we're proud to announce that Oak HC/FT led a $35 million Series A in Latitude, the global payments infrastructure company connecting stablecoin settlement to local payment rails worldwide.
Stablecoins have solved the middle of cross-border payments. The last mile – turning that settlement into money someone can actually spend – is still slow, expensive, or missing in most of the world. Latitude built that last mile: a single API that moves money into any market and lands it in local currency, in seconds, at transparent rates.
Before building go-to-market, the team spent its first year securing its own money transmitter licenses, reaching licensed or approved status across 45 U.S. markets in about eight months. That's the harder path – and the one that compounds.
We've tracked founders @cyril_mathew, Brian Wrightson, and Vivek Morzaria since before Latitude existed, and now we're proud to back them as they build.
Read more: oakhcft.com/blog-post/the-la…
We raised a $35M Series A led by @oakhcft . That brings our total capital raised to $43M.
We spent the last decade watching money get stuck at borders across roles at Uber, Coinbase, Stripe, and Zero Hash. Latitude (@rtp) is what we built with those lessons.
.@RilletHQ just announced a $100M Series C at a $1B valuation, marking a major milestone in the company’s growth and its vision for an AI-native ERP.
We caught up with Co-Founder & CEO @nicckopp to talk about what’s driving that growth and where Rillet is headed next. The company is betting that AI can do more than augment decades-old accounting software – it can fundamentally rebuild how finance gets done. Nic discusses Rillet’s push upmarket and what the ERP of the future might look like.
Read the full conversation: oakhcft.com/blog-post/rillet…
We're thrilled to present Differential, an invite-only gathering for 100 of the most promising early-stage health tech founders and builders, alongside @healthtechnerds.
October 1 in New York, we'll bring this group together for closed-door conversations on what it takes to build a resilient health tech company when AI, policy, capital markets, and buyer behavior are all shifting at once – plus real time built into the day to connect with other ambitious founders navigating the same terrain.
Apply to join us: differential.healthtechnerds…
We’re honored to share that Oak HC/FT has been named to @TIME's 2026 list of America’s Top Venture Capital Firms.
Now in its second year, the ranking recognizes the 350 leading VC firms in the country based on fundraising strength, investment activity, performance, and leadership.
We’re proud to be recognized alongside some of the industry’s most respected firms and grateful to the incredible entrepreneurs we partner with for making this possible.
Read the full list: time.com/article/2026/08/12/…
Thrilled to keep backing @nicckopp and the entire @RilletHQ team. This marks Oak HC/FT’s third consecutive round with Rillet, as the company closes a $100M Series C at a $1B valuation.
Since first backing Rillet at the Series A, we’ve watched the team execute at a pace that’s rare even by startup standards. The numbers behind this round are a testament to the team’s momentum: Rillet has raised three rounds in the last year, bringing total funding to more than $200M. The company has doubled new ARR in just three months and now serves 600+ customers.
Congratulations to Rillet on this incredible milestone. We couldn’t be more excited to continue building alongside you.
Today we're announcing our $100M Series C at a $1B valuation, led by @ICONIQCapital. It's our third round in 14 months and brings our total funding to over $200m
The round came together in less than 48 hours.
We weren't planning to raise. Then new ARR doubled last quarter and we crossed 600+ customers including public companies and enterprises with $2B in revenue. Rillet AI agent usage is growing 70% each month and CFOs are replacing Oracle Fusion, SAP and Workday to run their companies on Rillet.
We also announced our alliance with EY and officially partnered with more than half of the top 20 CPA firms.
@RilletHQ is creating an entirely new category of finance infrastructure. With Rillet, the ERP becomes the harness for the modern finance organization, where people and agents share the same financial data, apply the same accounting policies and controls, and work from a single, continuously updated view of the business. Agents perform increasingly complex financial work, while finance teams retain visibility, approval authority and a complete audit trail.
Thank you to our customers for believing in the mission and building the future of finance with us. We could not do this without you.
Thank you to the Rillet team. As I say often, building Rillet is our own version of sending rockets to Mars. It is incredibly difficult. You make it look easy.
Finally, thank you to our investors. To ICONIQ for leading the round and to our existing and new investors for building with us. @sequoia , @a16z, Sequoia Global Equities, @BainCapVC, @oakhcft, @BatteryVentures, @FirstMarkCap, @scalevp, and @creandum.
Back to work :)
Today, we're excited to announce that we're leading Dash Bio's $30M Series A.
Drug discovery has never moved faster, but turning a promising molecule into an approved medicine still relies on manual, hourly-priced work with timelines measured in months. Dash is changing that, starting with bioanalysis: the lab testing that measures a drug's safety and efficacy in preclinical and clinical samples.
Through custom robotics and proprietary software, Dash is reducing turnaround times from months to days while offering upfront pricing and sample-level transparency the industry hasn't seen before.
In less than a year since launch, Dash has signed more than 30 customers, including four of the world's top 25 pharmaceutical companies.
Led by CEO Dave Johnson (former Chief Data & AI Officer at Moderna), COO Ander Tallett, and CSO Ely Porter, this team has lived the problem they're solving. We couldn't be more excited to partner with them.
Read more: oakhcft.com/blog-post/unbloc…
Today, @candid_health announced a $120M Series D.
Medical billing is a $280B industry barely touched by real innovation since its software was built. Nick Perry and Doug Proctor built Candid to change that – pairing deterministic rules with agentic AI to automate the end-to-end claim lifecycle.
The results: Touchless Claim Rates as high as 97%, 6x/3x/2.5x consecutive years of revenue growth, and just one regrettable customer churn in seven years.
In our conversation, Nick and Doug discuss why billing systems are a black box, how they engineered that Touchless Claim Rate, and what it takes to stay ahead of changing insurance algorithms.
Read the full Q&A: oakhcft.com/blog-post/how-ca…